Print

AVEG 013A

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) April 04, 1993
gp160 Vaccine (Immuno-AG) Protein gp160 env B LAI, MN
gp160 Vaccine (Immuno-AG) Protein
USA 24
NCT00001037
https://clinicaltrials.gov/show/NCT00001037